

## Théa, OliX to develop RNAi therapies for AMD treatment

18 March 2019 | News

License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration (AMD).



OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, has announced that it has signed a license and collaboration agreement with Théa Open Innovation, part of the Laboratoires Théa S.A.S (Théa) which is the leading French independent pharmaceutical company in Europe dedicated to ophthalmology, to develop and commercialize OLX301A.

Under the agreement, OliX receives a non-refundable and non-creditable upfront payment of 2 million euro and is eligible to receive milestone payments upon achievement of clinical milestones, plus royalty for the development and commercialization.

Théa has been granted licensing rights for OLX301A program in EU countries, Middle East and Africa. OliX continues to hold the rights of OLX301A program for US and Asia.

Dong-ki Lee, the founder and CEO of OliX, stated, "OliX's cp-asiRNA platform technology is an RNAi platform optimal for the development of ocular therapeutics, which can circumvent potential side effects arising from the existing siRNA technology. The collaboration with Théa proves that OliX's ophthalmology RNAi platform has been recognized in global pharmaceutical market, and we will continue to expand pipelines for eye diseases."